BNET Industries
Market Cap:$633.5M
Last Fiscal Year Sales:$11.5M
- Public
- US
Dow Jones Description
This company's always right on target. Founded in 1982 and headquartered in Winston-Salem, NC, Targacept, Inc. (NASDAQ: TRGT) researches and develops drugs to be used to treat central nervous system conditions and diseases by focusing on three primary therapeutic areas: cognitive impairment, depression and anxiety, and pain. The drugs could ultimately improve diseases such as depression, hypertension, and Alzheimer's disease. The company completed an initial public offering of 5.0 million shares of common stock at $9.00 per share in April 2006, resulting in $45.0 million in gross proceeds. It has approximately 80 employees. In November 2005, it was named one of the ten AôBest Employers in North Carolina.'
Number of Employees 102
Contact Information
200 E 1st St Ste 300
Winston Salem, North Carolina 27101-4165
1 336 480 2100
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Targacept Releases 3Q 2009 Financial Results
-
Targacept shares soar on promising depression drug data
-
Targacept Unveils Stellar Depression Drug Data: BioBuzz
-
Drug tests raise hopes: Targacept TC-5214 shows promise as an add-on therapy
-
Today's report key to future for Targacept
-
Hapolim Securities Initiates Coverage on Targacept TRGT with a Buy
-
Data to be Presented on Multiple Targacept NNR Therapeutics at Society for Neuroscience Satellite Symposium
-
Wall Street News Alert: Trade Alert: TRGT, BEXP, GCI, INTC
News & Analysis
Filter by
targacept inc. - All News and Analysis
Targacept, Inc. Q3 2009 Earnings Call Transcript
Seeking Alpha
- 2009-11-05
Question-and-Answer SessionOperator Operator instructions Our first question comes from the line of Terence Flynn with Lazard Capital Markets. Please proceed. Terence Flynn – Lazard Capital Markets Hi, thanks for taking the questions and congrats on all the progress. I joined the call a little late, so I was just...
Expect Targacept to Move Higher
Seeking Alpha
- 2009-10-21
Dan Rosenblum submits: Having seen small biotech stocks Dov Pharma and Interneuron to name two that showed promising Phase 2 results in treatments for depression which ended up failing after the drugs advanced into Phase 3, I was somewhat skeptical of Targacept's TRGT rapid rise from $4...
Targacept, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-08-05
Earnings Call ExcerptTargacept, Inc. TRGT Q2 2009 Earnings Call August 5, 2009, 5:00 pm ET Executives Don deBethizy - President and CEO Alan Musso - VP, CFO and Treasurer Geoffrey Dunbar - VP, Clinical Development and Regulatory Affairs Analysts Bret Holley - Oppenheimer and Company Juan Sanchez - Ladenburg...
Targacept, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-08-05
Targacept, Inc. TRGT Q2 2009 Earnings Call August 5, 2009, 5:00 pm ET
Targacept, Inc. Q4 2008 Earnings Call Transcript
Seeking Alpha
- 2009-02-12
Question-and-Answer Session Operator Operator Instructions. And our first question comes from the line of Terence Flynn with Lazard Capital Markets. Please proceed sir. Terence Flynn – Lazard Capital Markets Hi, good afternoon. Thanks for taking the questions. Just wondering around some of the start of these Phase...
Targacept, Inc. Q3 2008 Earnings Call Transcript
Seeking Alpha
- 2008-11-20
Question-and-Answer SessionOperator Operator instructions And our first question will come from the line of Terence Flynn of Lazard Capital Markets. Please proceed. Terence Flynn – Lazard Capital Markets Hi, good afternoon. Just a couple of questions. I was just wondering if you could share with us –...
Targacept, Inc Q2 2008 Earnings Call Transcript
Seeking Alpha
- 2008-08-05
Question-and-Answer Session Operator Operator Instruction. Our first question comes from line of Terence Flynn from Lazard. Please proceed. Terence Flynn Hi, good afternoon. Thanks for taking my questions and congratulation on all the recent progress. First off, I just wanted on the 3480...
Targacept to Present at Three Upcoming Investor Conferences
- 2007-09-26
WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics TM, today announced that: * J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the "ThinkClinic" educational forum for healthcare investors sponsored by...
Targacept Inc
- 2002-09-01
J. Donald deBethizy, Ph.D., president and CEO of Targacept Inc. of Winston-Salem, has been named Ernst & Young's 2002 Carolinas' Emerging Entrepreneur of the Year. deBethizy was credited with championing the potential of neuronal nicotinic receptor research at R.J. Reynolds Tobacco Co. in Winston-Salem and forming Targacept around the technology.
Targacept Inc
- 2002-05-01
* Targacept Inc. of Winston-Salem recently moved out of R.J. Reynolds Tobacco space to One Technology Place in the Piedmont Triad Research Park. The company is leasing the top two floors of the building from Wake Forest University, which purchased the facility a year ago and upfitted space for Targacept's...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
